Troglitazone
Catalog No.
A3893
Selective PPARγ agonist
Featured Products
Troglitazone (CAS 97322-87-7) is a synthetic small molecule agonist of peroxisome proliferator-activated receptor gamma (PPARγ), and exhibits dual activity towards PPARγ/α. Primarily developed as a therapeutic agent for type 2 diabetes, it modulates lipid and glucose metabolism by activating nuclear receptor pathways. In vitro, troglitazone reduces proliferation and induces apoptosis in human renal carcinoma cells, suggesting potential anti-tumor functionality. In animal models, prolonged administration at high doses (400-800 mg/kg) promotes endothelial cell proliferation. Clinically, troglitazone has been investigated for safety and pharmacokinetics in patients with diabetes and liposarcoma.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 441.54 |
| Cas No. | 97322-87-7 |
| Formula | C24H27NO5S |
| Synonyms | Rezulin;CS-045;Noscal |
| Solubility | insoluble in H2O; ≥20.9 mg/mL in DMSO; ≥3.34 mg/mL in EtOH with gentle warming and ultrasonic |
| Chemical Name | 5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
| SDF | Download SDF |
| Canonical SMILES | CC1=C(C(=C2CCC(OC2=C1C)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C)O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Description | Troglitazone(CS-045) is a agonist of PPARγ. | |||||
| Targets | PPARγ | |||||
| IC50 | ||||||
Quality Control & MSDS
- View current batch:
Chemical structure
